Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Nephrology  |  Oncology  |  Family Medicine  |  Urology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Bladder Cancer Clinical Trials

A listing of Bladder Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (250) clinical trials

Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

Based on the results from the Phase 1 study of pazopanib combined with paclitaxel and the activity of paclitaxel in urothelial cancer, testing this regimen in a disease where there is an unmet need appears appropriate.

Phase

Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer

The intravesical treatment of bladder cancer with Abraxane is more desirable than other taxanes due to its ability to be diluted in water and not lipid-based solutions allowing it greater access to sites in the bladder. Thus, we are interested in investigating Abraxane's safety, toxicity, and efficacy profile for the ...

Phase

Effects of Structured Rehabilitation Program on Quality of Life in Rectal Cancer Patients- a Randomized Controlled Trial

Quality of life after rectal surgery is reported to be impaired. Side effects of surgery and/or neoadjuvant treatment as functional disturbances like sexual dysfunction, urinary incontinence, anal incontinence or stoma problems are commonly experienced. The investigators hypotheses is that structured rehabilitation program addressing these problems will improve quality of life. ...

Phase N/A

Biomarkers and Radiation Side Effects in Patients Undergoing Radiation Therapy for Gastrointestinal Cancer

OBJECTIVES: Primary - Determine if tumor-specific DNA mutations and aberrant DNA methylation can be detected in the serum, urine, or stool at the time of diagnosis in patients undergoing radiotherapy for gastrointestinal malignancies. - Determine if changes in mutational status at follow up are associated with disease persistence, recurrence, or ...

Phase N/A

Single Agent Abraxane as Second Line Therapy in Bladder Cancer

For those patients with advanced bladder cancer who have progressed on a platinum based regimen, no widely accepted standard second line therapy currently exists. Taxanes including paclitaxel have exhibited clinical activity in this disease and are sometimes given off study. However, toxicities including neurotoxicity and hypersensitivity reactions often limit the ...

Phase

Tamoxifen in Treating Patients With Metastatic Bladder Cancer That Did Not Respond to Previous Chemotherapy

OBJECTIVES: Primary - To assess the 4-month freedom from progression in patients with progressive metastatic transitional cell carcinoma of the bladder treated with tamoxifen citrate. Secondary - To determine the objective response rate. - To correlate response with estrogen-receptor status of the metastatic tumor. - To collect data on the ...

Phase

Hexvix Cystoscopy for Detection of Bladder Cancer

Hexvix is a photo-dynamic agent which fluoresces and is taken by tumor tissue in the bladder. When viewed under blue light cystoscopy, tumor areas appear red.

Phase

Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer

Primary Objective: - To analyse time to tumor progression in patients cystectomized for locally advanced TCC of the bladder, who are not suitable for cisplatin-based chemotherapy (i.e. postoperative reduced renal function, advanced age). Patients are randomized to receive either adjuvant Gemcitabine immediately after radical operation (treatment arm A) or no ...

Phase

HAI Via Interventionally Implanted Port Catheter Systems

Inclusion criteria: - histologically confirmed hepatic cancer without symptomatic extrahepatic manifestation. - non-resectable disease or hepatic resection or ablation in between the past 8 weeks. - measurable disease (at least before hepatic resection) - Karnofsky performance status => 70%, or ECOG status 0-2 - >18 years of age - life ...

Phase

Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

To establish significant correlations between genetic polymorphisms and cancer, a largescale, systematic comparison of genetic alterations utilizing a case-control methodology is proposed. To date, such studies have been limited due to the large number of samples necessary for obtaining statistical significance, and the lack of rapid and accurate methods to ...

Phase N/A